Abstract
Introduction: Steroid 5-alpha reductase deficiency (5α-R2D) is a rare condition caused by genetic variants that reduce the activity of the enzyme that converts testosterone into dihydrotestosterone. The clinical spectrum of 5α-R2D is known to overlap with other 46,XY differences of sex development (DSD) such as androgen insensitivity or gonadal dysgenesis. However, the clinical trajectories of the aetiologies can differ, with 5α-R2D presenting its own challenges. Methods: In this study, we have collated clinical information for five individuals with variants in SRD5A2 identified using research genetic testing in an Australian paediatric setting. Results: We describe how a genetic finding resolved or confirmed a diagnosis for these individuals and how it guided clinical management and family counselling. Conclusion: This work highlights the importance of early genetic testing in children born with 46,XY DSD where it complements traditional first-line testing.
Journal Section:
Original Article
References
1.
Abacı
A
, Çatlı
G
, Kırbıyık
Ö
, Şahin
NM
, Abalı
ZY
, Ünal
E
, . Genotype-phenotype correlation, gonadal malignancy risk, gender preference, and testosterone/dihydrotestosterone ratio in steroid 5-alpha-reductase type 2 deficiency: a multicenter study from Turkey
. J Endocrinol Invest
. 2019
;42
(4
):453
–70
. https://doi.org/10.1007/s40618-018-0940-y.
2.
Batista
RL
, Mendonca
BB
. Integrative and analytical review of the 5-alpha-reductase type 2 deficiency worldwide
. Appl Clin Genet
. 2020
;13
:83
–96
. https://doi.org/10.2147/tacg.s198178.
3.
Bertelloni
S
, Russo
G
, Baroncelli
GI
. Human chorionic gonadotropin test: old uncertainties, new perspectives, and value in 46,XY disorders of sex development
. Sex Dev
. 2018
;12
(1–3
):41
–9
. https://doi.org/10.1159/000481552.
4.
Blackless
M
, Charuvastra
A
, Derryck
A
, Fausto-Sterling
A
, Lauzanne
K
, Lee
E
. How sexually dimorphic are we? Review and synthesis
. Am J Hum Biol
. 2000
;12
(2
):151
–66
. https://doi.org/10.1002/(sici)1520-6300(200003/04)12:2<151::aid-ajhb1>3.0.co;2-f.
5.
Byers
HM
, Mohnach
LH
, Fechner
PY
, Chen
M
, Thomas
IH
, Ramsdell
LA
, . Unexpected ethical dilemmas in sex assignment in 46,XY DSD due to 5-alpha reductase type 2 deficiency
. Am J Med Genet
. 2017
;175
:260
–7
. https://doi.org/10.1002/ajmg.c.31560.
6.
Chan
AOK
, But
BWM
, Lee
C-Y
, Lam
YY
, Ng
KL
, Tung
JYL
, . Diagnosis of 5α-reductase 2 deficiency: is measurement of dihydrotestosterone essential
. Clin Chem
. 2013
;59
(5
):798
–806
. https://doi.org/10.1373/clinchem.2012.196501.
7.
Cocchetti
C
, Ristori
J
, Mazzoli
F
, Prunas
A
, Bertelloni
S
, Magini
A
, . 5α-Reductase-2 deficiency: is gender assignment recommended in infancy? Two case-reports and review of the literature
. J Endocrinol Invest
. 2020
;43
(8
):1131
–6
. https://doi.org/10.1007/s40618-020-01193-w.
8.
Eggers
S
, Sadedin
S
, van den Bergen
JA
, Robevska
G
, Ohnesorg
T
, Hewitt
J
, . Disorders of sex development: insights from targeted gene sequencing of a large international patient cohort
. Genome Biol
. 2016
;17
(1
):243
. https://doi.org/10.1186/s13059-016-1105-y.
9.
Eunice
M
, Philibert
P
, Kulshreshtha
B
, Audran
F
, Paris
F
, Khurana
ML
, . Molecular diagnosis of 5α-reductase-2 gene mutation in two Indian families with male pseudohermaphroditism
. Asian J Androl
. 2008
;10
(5
):815
–8
. https://doi.org/10.1111/j.1745-7262.2008.00350.x.
10.
Fan
L
, Song
Y
, Polak
M
, Li
L
, Ren
X
, Zhang
B
, . Clinical characteristics and genotype-phenotype correlations of 130 Chinese children in a high-homogeneity single-center cohort with 5α-reductase 2 deficiency
. Mol Genet Genomic Med
. 2020
;8
(10
):e1431
. https://doi.org/10.1002/mgg3.1431.
11.
Imperato-McGinley
J
, Zhu
YS
. Androgens and male physiology the syndrome of 5α-reductase-2 deficiency
. Mol Cell Endocrinol
. 2002
;198
(1–2
):51
–9
. https://doi.org/10.1016/s0303-7207(02)00368-4.
12.
Katharopoulos
E
, Sauter
K
, Pandey
AV
, Flück
CE
. In silico and functional studies reveal novel loss-of-function variants of SRD5A2, but no variants explaining excess 5α-reductase activity
. J Steroid Biochem Mol Biol
. 2019
;190
:263
–72
. https://doi.org/10.1016/j.jsbmb.2019.01.017.
13.
Maimoun
L
, Philibert
P
, Cammas
B
, Audran
F
, Bouchard
P
, Fenichel
P
, . Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients
. J Clin Endocrinol Metab
. 2011
;96
(2
):296
–307
. https://doi.org/10.1210/jc.2010-1024.
14.
Makridakis
NM
, di Salle
E
, Reichardt
JK
. Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II
. Pharmacogenetics
. 2000
;10
:407
–13
. https://doi.org/10.1097/00008571-200007000-00004.
15.
Marzuki
NS
, Idris
FP
, Kartapradja
HD
, Harahap
AR
, Batubara
JRL
. Characterising SRD5A2 gene variants in 37 Indonesian patients with 5-alpha-reductase type 2 deficiency
. Int J Endocrinol
. 2019
;2019
:7676341
. https://doi.org/10.1155/2019/7676341.
16.
Matsubara
K
, Iwamoto
H
, Yoshida
A
, Ogata
T
. Semen analysis and successful paternity by intracytoplasmic sperm injection in a man with steroid 5α-reductase-2 deficiency
. Fertil Steril
. 2010
;94
(7
):2770.e7
–10
. https://doi.org/10.1016/j.fertnstert.2010.04.013.
17.
McGee
LM
, Lin-Brande
M
, Woods
K
, Seideman
CA
. Pubertal suppression and surgical management of a patient with 5-alpha reductase deficiency
. Urology
. 2022
;165
:e29
-31
. https://doi.org/10.1016/j.urology.2022.03.019.
18.
Mendonca
BB
, Batista
RL
, Domenice
S
, Costa
EMF
, Arnhold
IJP
, Russell
DW
, . Steroid 5α-reductase 2 deficiency
. J Steroid Biochem Mol Biol
. 2016
;163
:206
–11
. https://doi.org/10.1016/j.jsbmb.2016.05.020.
19.
O’Connell
MA
, Atlas
G
, Ayers
K
, Sinclair
A
. Establishing a molecular genetic diagnosis in children with differences of sex development-a clinical approach
. Horm Res Paediatr
. 2021
.
20.
Oliveira
LR
, Longui
CA
, Guaragna-Filho
G
, Costa
JL
, Lanaro
R
, Silva
DA
, . Androgens by immunoassay and mass spectrometry in children with 46,XY disorder of sex development
. Endocr Connect
. 2020
;9
(11
):1085
–94
. https://doi.org/10.1530/ec-20-0454.
21.
Shabir
I
, Khurana
ML
, Joseph
AA
, Eunice
M
, Mehta
M
, Ammini
AC
. Phenotype, genotype and gender identity in a large cohort of patients from India with 5α-reductase 2 deficiency
. Andrology
. 2015
;3
(6
):1132
–9
. https://doi.org/10.1111/andr.12108.
22.
Skordis
N
, Shammas
C
, Efstathiou
E
, Sertedaki
A
, Neocleous
V
, Phylactou
L
. Late diagnosis of 5alpha steroid-reductase deficiency due to IVS12A>G mutation of the SRD5a2 gene in an adolescent girl presented with primary amenorrhea
. Hormones (Athens)
. 2011
;10
(3
):230
–5
. https://doi.org/10.14310/horm.2002.1313.
23.
van den Bergen
JA
, Robevska
G
, Eggers
S
, Riedl
S
, Grover
SR
, Bergman
PB
, . Analysis of variants in GATA4 and FOG2/ZFPM2 demonstrates benign contribution to 46,XY disorders of sex development
. Mol Genet Genomic Med
. 2020
;8
(3
):e1095
. https://doi.org/10.1002/mgg3.1095.
24.
Walter
KN
, Kienzle
FB
, Frankenschmidt
A
, Hiort
O
, Wudy
SA
, van der Werf-Grohmann
N
, . Difficulties in diagnosis and treatment of 5α-reductase type 2 deficiency in a newborn with 46, XY DSD
. Horm Res Paediatr
. 2010
;74
(1
):67
–71
. https://doi.org/10.1159/000313372.
25.
Wigley
WC
, Prihoda
JS
, Mowszowicz
I
, Mendonça
BB
, New
MI
, Wilson
JD
, . Natural mutagenesis study of the human steroid 5 alpha-reductase 2 isozyme
. Biochemistry
. 1994
;33
(5
):1265
–70
. https://doi.org/10.1021/bi00171a029.
26.
Wildeman
M
, van Ophuizen
E
, den Dunnen
JT
, Taschner
PEM
. Improving sequence variant descriptions in mutation databases and literature using the Mutalyzer sequence variation nomenclature checker
. Hum Mutat
. 2008
;29
(1
):6
–13
. https://doi.org/10.1002/humu.20654.
27.
Wolffenbuttel
KP
, Hersmus
R
, Stoop
H
, Biermann
K
, Hoebeke
P
, Cools
M
, . Gonadal dysgenesis in disorders of sex development: diagnosis and surgical management
. J Pediatr Urol
. 2016
;12
(6
):411
–6
. https://doi.org/10.1016/j.jpurol.2016.08.015.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
